From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

Melissa Bersanelli, Sebastiano Buti, Melissa Bersanelli, Sebastiano Buti

Abstract

After that the era of chemotherapy in the treatment of solid tumors have been overcome by the "translational era", with the innovation introduced by targeted therapies, medical oncology is currently looking at the dawn of a new "immunotherapy era" with the advent of immune checkpoint inhibitors (CKI) antibodies. The onset of PD-1/PD-L1 targeted therapy has demonstrated the importance of this axis in the immune escape across almost all human cancers. The new CKI allowed to significantly prolong survival and to generate durable response, demonstrating remarkable efficacy in a wide range of cancer types. The aim of this article is to review the most up to date literature about the clinical effectiveness of CKI antibodies targeting PD-1/PD-L1 axis for the treatment of advanced solid tumors and to explore transversal challenges in the immune checkpoint blockade.

Keywords: Anti-PD-1 antibodies; Anti-PD-L1 antibodies; Cancer treatment; Checkpoint inhibitors; Immune checkpoint blockade; Immune checkpoint inhibitors; PD-1; PD-L1.

Conflict of interest statement

Conflict-of-interest statement: No potential conflicts of interest. No financial support.

References

    1. Lee CS, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 2013;76:233–247.
    1. Naing A, Gelderblom H, Gainor J, Forde PM, Butler M, Lin CC, Sharma S, Ochoa de Olza M, Schellens JHM, Soria JC, et al. A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors. 2016 ASCO Annual Meeting, Poster Discussion. J Clin Oncol. 2016;34 Suppl:abstr 3060.
    1. Eli Lilly and Company. A study of anti-PD-L1 checkpoint antibody (LY3300054) alone and in combination in participants with advanced refractory solid tumors (PACT). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
    1. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–3895.
    1. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–477.
    1. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
    1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
    1. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384.
    1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521–2532.
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23–34.
    1. Bristol-Myers Squibb. A study of two different dose combinations of nivolumab in combination with ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Italian Network for Tumor Biotherapy Foundation. A study of fotemustine (FTM) vs FTM and ipilimumab (IPI) or IPI an nivolumab in melanoma brain metastasis (NIBIT-M2). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Canadian Cancer Trials Group. Duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Incyte Corporation. A phase 3 study of pembrolizumab epacadostat or placebo in subjects with unresectable or metastatic melanoma. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Amgen. Pembrolizumab with or without talimogene laherparepvec or talimogene laherparepvec placebo in unresected melanoma (MASTERKEY-265). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. National Cancer Institute (NCI) A randomized phase III trial of dabrafenib trametinib followed by ipilimumab nivolumab at progression vs ipilimumab nivolumab followed by dabrafenib trametinib at progression in patients with advanced BRAFV600 mutant melanoma. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. FDA approves Yervoy to reduce the risk of melanoma returning after surgery. [released 2015 Oct 28] Available from: .
    1. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. National Cancer Institute (NCI) High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. RTOG Foundation, Inc. Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. National Cancer Institute (NCI) Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. A Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. AstraZeneca. A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Canadian Cancer Trials Group. Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016;21:821–833.
    1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123–135.
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627–1639.
    1. ESMO 2016 Press Release. Significant survival gains with atezolizumab vs docetaxel for non-small cell lung cancer [updated 2016 Oct 9] Available from: .
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823–1833.
    1. Bristol-Myers Squibb. An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1 Non-Small Cell Lung Cancer (CheckMate 026). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Eisai Inc. Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. tudy of Platinum Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) Versus Investigator’s Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Pfizer. A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Pfizer. Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Pfizer. A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Pfizer. A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. EMD Serono Research & Development Institute, Inc. Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. EMD Serono Research & Development Institute, Inc. Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. EMD Serono Research & Development Institute, Inc. Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. EMD Serono Research & Development Institute, Inc. Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Randomized Phase 3 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - “OAK”. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study of Atezolizumab Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (IMvigor211). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy [IMvigor130]. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study of Atezolizumab (MPDL3280A) Compared With Gemcitabine Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower111]. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study of Atezolizumab in Combination With Carboplatin Paclitaxel or Carboplatin Nab-paclitaxel Compared With Carboplatin Nab-paclitaxel in Participants With Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) [IMpower 131]. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy [IMpower210]. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Non-Squamous Non-Small Cell Lung Cancer (IMpower130). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab Paclitaxel Compared With Placebo With Nab Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer (IMpassion130). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study Of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Hoffmann-La Roche. A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. AstraZeneca. Phase III Open-label Study of MEDI4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. AstraZeneca. Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. AstraZeneca. Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Southwest Oncology Group. Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. AstraZeneca. Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. AstraZeneca. Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. AstraZeneca. Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. AstraZeneca. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Merck Sharp & Dohme Corp. A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. A Study of Nivolumab Compared to Sorafenib as a Primary Treatment in Patients With Advanced Hepatocellular Carcinoma. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Ono Pharmaceutical Co. Ltd. Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Ono Pharmaceutical Co. Ltd. Study of ONO-4538 in Unresectable Advanced or Recurrent Esophageal Cancer. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Trial of Nivolumab vs Therapy of Investigator’s Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. A Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. A Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (CheckMate 451). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Study of Nivolumab Compared to Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer (CheckMate331). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer (CheckMate 078). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. National Cancer Institute (NCI) Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery. In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Bristol-Myers Squibb. Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (CheckMate 401). In: [Internet]. Bethesda (MD): National Library of Medicine (US) Available from: .
    1. Buti S, Bersanelli M. The ‘nivolution’ in renal cell carcinoma: behind the scenes of clinical trials. Future Oncol. 2016;12:2061–2063.
    1. Facchinetti F, Marabelle A, Rossi G, Soria JC, Besse B, Tiseo M. Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. J Thorac Oncol. 2016;11:1819–1836.
    1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1803–1813.
    1. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–1482.
    1. Buti S, Bersanelli M. Combination therapy in kidney cancer: the next revolution? Lancet Oncol. 2015;16:1441–1442.
    1. A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) NCT02853331.
    1. Kim J. Immune checkpoint blockade therapy for bladder cancer treatment. Investig Clin Urol. 2016;57 Suppl 1:S98–S105.
    1. Fahmy O, Khairul-Asri MG, Stenzl A, Gakis G. The current status of checkpoint inhibitors in metastatic bladder cancer. Clin Exp Metastasis. 2016;33:629–635.
    1. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920.
    1. Economopoulou P, Kotsantis I, Psyrri A. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Curr Treat Options Oncol. 2016;17:40.
    1. Hamanishi J, Mandai M, Konishi I. Immune checkpoint inhibition in ovarian cancer. Int Immunol. 2016;28:339–348.
    1. Burgess M, Gorantla V, Weiss K, Tawbi H. Immunotherapy in Sarcoma: Future Horizons. Curr Oncol Rep. 2015;17:52.
    1. Matsuki E, Younes A. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Curr Treat Options Oncol. 2016;17:31.
    1. Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer. 2016;4:14.
    1. Sanchez-Castañón M, Er TK, Bujanda L, Herreros-Villanueva M. Immunotherapy in colorectal cancer: What have we learned so far? Clin Chim Acta. 2016;460:78–87.
    1. Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B. Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel) 2016;11:108–115.
    1. Helissey C, Vicier C, Champiat S. The development of immunotherapy in older adults: New treatments, new toxicities? J Geriatr Oncol. 2016;7:325–333.
    1. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One. 2016;11:e0160221.
    1. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559–574.
    1. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016;34:1510–1517.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247.
    1. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.
    1. Ades F, Yamaguchi N. WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results? Ecancermedicalscience. 2015;9:604.
    1. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015;10:e0130142.
    1. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567.
    1. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV, et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol. 2016;34:833–842.
    1. Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, et al. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clin Cancer Res. 2015;21:3969–3976.
    1. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509–2520.
    1. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51.
    1. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D’Andrea AD, Wu CJ, et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319–1323.
    1. Harris SJ, Brown J, Lopez J, Yap TA. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016;13:171–193.
    1. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother. 2009;58:1219–1228.
    1. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One. 2009;4:e6982.
    1. Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21:1128–1138.
    1. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28:690–714.
    1. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862–870.
    1. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–931.
    1. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:1270–1271.
    1. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. 8th ed. Elsevier. ISBN-13 987-0323222754.
    1. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–530.
    1. van der Most RG, Currie AJ, Robinson BW, Lake RA. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 2008;15:13–20.
    1. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) Ann Oncol. 2016;27:1492–1504.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する